Pan-Cancer Multi-Omics Agent
The Pan-Cancer Multi-Omics Agent integrates multi-omics data across cancer types to identify shared oncogenic drivers, discover novel subtypes, and enable cross-cancer therapeutic insights. It leverages TCGA, CPTAC, and other pan-cancer resources with deep learning for comprehensive cancer characterization.
When to Use This Skill
- When analyzing patient tumors in context of pan-cancer molecular profiles.
- To identify shared drivers and vulnerabilities across cancer types.
- For discovering novel molecular subtypes that span histological boundaries.
- When prioritizing therapeutic targets with pan-cancer evidence.
- To benchmark single-cancer findings against pan-cancer patterns.
Core Capabilities
Pan-Cancer Subtyping: ML-based clustering across 32+ cancer types to identify molecular subtypes transcending tissue of origin.
Driver Discovery: Integrate mutation, expression, and CNV data to identify oncogenic drivers using pan-cancer statistical power.
Multi-Omics Fusion: Deep learning integration of mRNA, miRNA, methylation, and protein data for comprehensive profiles.
Pathway Analysis: Identify dysregulated pathways with pan-cancer prevalence and therapeutic implications.
Survival Modeling: PRISM framework for multi-omics prognostic marker discovery and survival prediction.
Therapeutic Matching: Map patient profiles to pan-cancer drug sensitivity data and clinical trial evidence.
TCGA Pan-Cancer Atlas Integration
| Data Type |
Samples |
Application |
| Somatic mutations |
11,000+ |
Driver identification |
| Copy number |
11,000+ |
Amplifications/deletions |
| mRNA expression |
11,000+ |
Expression subtypes |
| miRNA expression |
10,000+ |
Regulatory networks |
| DNA methylation |
10,000+ |
Epigenetic subtypes |
| Protein (RPPA) |
8,000+ |
Pathway activation |
Workflow
Input: Patient multi-omics data (mutations, CNV, expression, methylation).
Normalization: Harmonize data to TCGA reference standards.
Classification: Assign to pan-cancer molecular subtypes.
Driver Analysis: Identify patient-specific drivers in pan-cancer context.
Pathway Scoring: Calculate pathway activation scores.
Therapeutic Matching: Identify actionable targets and trial matches.
Output: Pan-cancer classification, driver report, pathway profiles, treatment recommendations.
Example Usage
User: "Classify this breast cancer patient's tumor in the pan-cancer context and identify shared drivers."
Agent Action:
python3 Skills/Oncology/Pan_Cancer_MultiOmics_Agent/pancancer_analyzer.py \
--mutations patient_mutations.maf \
--expression patient_rnaseq.tsv \
--methylation patient_methylation.tsv \
--cnv patient_cnv_segments.tsv \
--reference tcga_pancancer \
--subtype_method nmf_consensus \
--output pancancer_report/
Pan-Cancer Molecular Subtypes
Cross-cancer molecular taxonomy identifies patterns beyond histology:
| Subtype |
Characteristics |
Example Cancers |
| C1-Wound healing |
High proliferation, MYC amp |
Breast, ovarian, bladder |
| C2-IFN-gamma dominant |
Immune active, high TCR/BCR |
Melanoma, lung, cervical |
| C3-Inflammatory |
NF-kB, cytokine signatures |
Head/neck, stomach |
| C4-Lymphocyte depleted |
Low immune, PTEN loss |
Glioma, uveal melanoma |
| C5-Immunologically quiet |
Low expression overall |
Kidney chromophobe, thyroid |
| C6-TGF-beta dominant |
High TGF-B, fibrosis |
Pancreas, rectum, glioma |
Deep Learning Architecture
Multi-Omics Integration Model:
Input Layers:
- Genomic encoder (mutations, CNV)
- Transcriptomic encoder (mRNA, miRNA)
- Epigenomic encoder (methylation)
- Proteomic encoder (RPPA)
Fusion Layer:
- Cross-attention mechanism
- Multi-modal variational autoencoder
Output Heads:
- Subtype classifier
- Survival predictor
- Drug response predictor
MLOmics Database Access
The agent integrates with MLOmics, providing:
- 8,314 patient samples across 32 cancer types
- Pre-computed features for ML benchmarking
- Standardized train/test splits for reproducibility
- Drug sensitivity data for 300+ compounds
Prerequisites
- Python 3.10+
- PyTorch with multi-modal architectures
- Access to TCGA, CPTAC, or local data
- 16GB+ RAM for pan-cancer analysis
Related Skills
- Tumor_Clonal_Evolution - For intratumoral heterogeneity
- Multi_Omics_Integration - For single-patient integration
- Drug_Repurposing - For therapeutic matching
Clinical Applications
- Cancer of Unknown Primary (CUP): Identify tissue of origin
- Cross-indication trials: Find basket trial eligibility
- Driver prioritization: Pan-cancer functional evidence
- Prognosis: Multi-omics survival models
Author
AI Group - Biomedical AI Platform
1---2name: pan-cancer-multiomics-agent3description: AI-powered pan-cancer analysis integrating genomic, transcriptomic, proteomic, and epigenomic data for cancer subtyping, driver identification, and cross-cancer pattern discovery.4---56<!--7# COPYRIGHT NOTICE8# This file is part of the "Universal Biomedical Skills" project.9# Copyright (c) 2026 MD BABU MIA, PhD <md.babu.mia@mssm.edu>10# All Rights Reserved.11#12# This code is proprietary and confidential.13# Unauthorized copying of this file, via any medium is strictly prohibited.14#15# Provenance: Authenticated by MD BABU MIA1617-->18192021# Pan-Cancer Multi-Omics Agent2223The **Pan-Cancer Multi-Omics Agent** integrates multi-omics data across cancer types to identify shared oncogenic drivers, discover novel subtypes, and enable cross-cancer therapeutic insights. It leverages TCGA, CPTAC, and other pan-cancer resources with deep learning for comprehensive cancer characterization.2425## When to Use This Skill2627* When analyzing patient tumors in context of pan-cancer molecular profiles.28* To identify shared drivers and vulnerabilities across cancer types.29* For discovering novel molecular subtypes that span histological boundaries.30* When prioritizing therapeutic targets with pan-cancer evidence.31* To benchmark single-cancer findings against pan-cancer patterns.3233## Core Capabilities34351. **Pan-Cancer Subtyping**: ML-based clustering across 32+ cancer types to identify molecular subtypes transcending tissue of origin.36372. **Driver Discovery**: Integrate mutation, expression, and CNV data to identify oncogenic drivers using pan-cancer statistical power.38393. **Multi-Omics Fusion**: Deep learning integration of mRNA, miRNA, methylation, and protein data for comprehensive profiles.40414. **Pathway Analysis**: Identify dysregulated pathways with pan-cancer prevalence and therapeutic implications.42435. **Survival Modeling**: PRISM framework for multi-omics prognostic marker discovery and survival prediction.44456. **Therapeutic Matching**: Map patient profiles to pan-cancer drug sensitivity data and clinical trial evidence.4647## TCGA Pan-Cancer Atlas Integration4849| Data Type | Samples | Application |50|-----------|---------|-------------|51| Somatic mutations | 11,000+ | Driver identification |52| Copy number | 11,000+ | Amplifications/deletions |53| mRNA expression | 11,000+ | Expression subtypes |54| miRNA expression | 10,000+ | Regulatory networks |55| DNA methylation | 10,000+ | Epigenetic subtypes |56| Protein (RPPA) | 8,000+ | Pathway activation |5758## Workflow59601. **Input**: Patient multi-omics data (mutations, CNV, expression, methylation).61622. **Normalization**: Harmonize data to TCGA reference standards.63643. **Classification**: Assign to pan-cancer molecular subtypes.65664. **Driver Analysis**: Identify patient-specific drivers in pan-cancer context.67685. **Pathway Scoring**: Calculate pathway activation scores.69706. **Therapeutic Matching**: Identify actionable targets and trial matches.71727. **Output**: Pan-cancer classification, driver report, pathway profiles, treatment recommendations.7374## Example Usage7576**User**: "Classify this breast cancer patient's tumor in the pan-cancer context and identify shared drivers."7778**Agent Action**:79```bash80python3 Skills/Oncology/Pan_Cancer_MultiOmics_Agent/pancancer_analyzer.py \81 --mutations patient_mutations.maf \82 --expression patient_rnaseq.tsv \83 --methylation patient_methylation.tsv \84 --cnv patient_cnv_segments.tsv \85 --reference tcga_pancancer \86 --subtype_method nmf_consensus \87 --output pancancer_report/88```8990## Pan-Cancer Molecular Subtypes9192Cross-cancer molecular taxonomy identifies patterns beyond histology:9394| Subtype | Characteristics | Example Cancers |95|---------|-----------------|-----------------|96| C1-Wound healing | High proliferation, MYC amp | Breast, ovarian, bladder |97| C2-IFN-gamma dominant | Immune active, high TCR/BCR | Melanoma, lung, cervical |98| C3-Inflammatory | NF-kB, cytokine signatures | Head/neck, stomach |99| C4-Lymphocyte depleted | Low immune, PTEN loss | Glioma, uveal melanoma |100| C5-Immunologically quiet | Low expression overall | Kidney chromophobe, thyroid |101| C6-TGF-beta dominant | High TGF-B, fibrosis | Pancreas, rectum, glioma |102103## Deep Learning Architecture104105**Multi-Omics Integration Model**:106```107Input Layers:108 - Genomic encoder (mutations, CNV)109 - Transcriptomic encoder (mRNA, miRNA)110 - Epigenomic encoder (methylation)111 - Proteomic encoder (RPPA)112113Fusion Layer:114 - Cross-attention mechanism115 - Multi-modal variational autoencoder116117Output Heads:118 - Subtype classifier119 - Survival predictor120 - Drug response predictor121```122123## MLOmics Database Access124125The agent integrates with MLOmics, providing:126- 8,314 patient samples across 32 cancer types127- Pre-computed features for ML benchmarking128- Standardized train/test splits for reproducibility129- Drug sensitivity data for 300+ compounds130131## Prerequisites132133* Python 3.10+134* PyTorch with multi-modal architectures135* Access to TCGA, CPTAC, or local data136* 16GB+ RAM for pan-cancer analysis137138## Related Skills139140* Tumor_Clonal_Evolution - For intratumoral heterogeneity141* Multi_Omics_Integration - For single-patient integration142* Drug_Repurposing - For therapeutic matching143144## Clinical Applications1451461. **Cancer of Unknown Primary (CUP)**: Identify tissue of origin1472. **Cross-indication trials**: Find basket trial eligibility1483. **Driver prioritization**: Pan-cancer functional evidence1494. **Prognosis**: Multi-omics survival models150151## Author152153AI Group - Biomedical AI Platform154155156<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->